Short answer: No. Providing a reagent, cell line, animal model, antibody, plasmid, or other physical research material to a collaborator — on its own — does not meet the threshold for authorship under the criteria used by the International Committee of Medical Journal Editors (ICMJE) and adopted, in substance, by most biomedical and life-sciences journals. Supplying materials is a real, often costly and time-consuming contribution, and it deserves formal credit — but the credit mechanism it maps to is acknowledgment or a CRediT Resources role, not co-authorship, unless the person who supplied the material also contributed to the work in one of the ways ICMJE actually requires.
This is one of the more common sources of friction in wet-lab and pre-clinical collaborations: a lab that spent years developing a knockout mouse line, or holds a hard-to-obtain patient cohort, or maintains a proprietary cell line, reasonably feels that access to that resource was essential to the resulting paper — and essential is not the same as authorship-qualifying. This guide sets out why, what the correct credit mechanism actually is, and how to handle it before it becomes a dispute.
The four ICMJE criteria, and where “providing materials” does and doesn’t fit
ICMJE’s authorship criteria require that an author meet all four of the following:
- Substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data;
- Drafting the work or reviewing it critically for important intellectual content;
- Final approval of the version to be published; and
- Agreement to be accountable for all aspects of the work, including ensuring that questions about its accuracy or integrity are investigated and resolved.
Handing over a vial of cells or a cohort of animals does not, by itself, satisfy any of the four. It is not conception or design of the study. It is not data acquisition, analysis, or interpretation — the material is an input to those steps, not the step itself. It is not drafting or critical review of the manuscript. And it does not carry accountability for the work’s accuracy or integrity, since the material supplier typically had no role in generating or interpreting the results the paper reports.
ICMJE’s own guidance is explicit that certain real, valuable contributions are not sufficient for authorship on their own: its current recommendations state that “examples of activities that alone (without other contributions) do not qualify a contributor for authorship are acquisition of funding; general supervision of a research group or general administrative support; and writing assistance, technical editing, language editing, and proofreading.” Provision of study materials or patients sits in the same category — a widely used formulation, traceable to ICMJE’s own earlier recommendations and still echoed in many journals’ author-contribution instructions, names “provision of study materials or patients” explicitly alongside data collection and general supervision as contributions that, standing alone, do not meet the authorship bar. The underlying principle hasn’t changed even where the exact wording of ICMJE’s published examples list has been trimmed over successive revisions: a contribution has to reach conception/design, analysis/interpretation, or drafting/critical review — not just enable someone else to do those things.
The correct way to credit resource provision: CRediT’s Resources role
The CRediT taxonomy (ANSI/NISO Z39.104-2022), which CASRAI originated and NISO now maintains, has a contributor role built for exactly this situation. The Resources role is operationally defined as “provision of study materials, reagents, materials, patients, laboratory samples, animals, instrumentation, computing resources, or other analysis tools.” This is the mechanism designed to make a real contribution visible and citable without collapsing the distinction between authorship and contributorship.
In practice, a journal that has adopted CRediT (most major biomedical and life-sciences publishers now have) will let you list a contributor’s name in the author-contributions statement with a Resources tag — alongside Funding acquisition for a grant holder who didn’t design the study, or Writing – review & editing for someone who only proofread. None of these on their own put a name in the byline; all of them are searchable, attributable, machine-readable credit that shows up in the paper’s metadata and, increasingly, in funder and institutional research-information systems. For a journal that hasn’t adopted CRediT, the equivalent is a named entry in the acknowledgments section (see CASRAI’s acknowledgments section entry) — for example, “We thank Dr. X for providing the Y knockout mouse line used in this study.”
When resource provision does combine into authorship — and when it doesn’t
The question is never “did this person provide materials,” it’s “did this person also do one of the other three things.” Two common real-world patterns illustrate the line:
- Does not qualify: A core facility or collaborating lab ships a validated reagent, antibody, or cell line on request, with no further involvement in the study’s design, execution, analysis, or writing. This is Resources-only. Even if the material is rare, expensive, or took years to develop, scarcity and effort do not substitute for intellectual contribution to the specific paper in question.
- Does qualify: A collaborator provides a proprietary animal model and consults on the experimental design that uses it, reviews and interprets the resulting data, and critically revises the manuscript draft. Here the material supplier has independently satisfied criteria 1, 2, and (if they review the final version and accept accountability) 3 and 4 as well — the resource was simply one part of a broader, genuine collaboration. The authorship claim rests on that broader collaboration, not on the material transfer itself.
This is also why many journals and institutions now ask corresponding authors to complete a structured CRediT statement rather than a single free-text acknowledgment paragraph: it forces an explicit, role-by-role accounting of who did what, which surfaces Resources-only contributions before they get conflated with authorship by default or by habit.
Practical steps: settling this before the manuscript is drafted
Most of the friction here is avoidable with an early, explicit conversation, ideally before the material changes hands:
- Put it in the Material Transfer Agreement (MTA) or an accompanying email. A standard Material Transfer Agreement governs IP, use restrictions, and liability for the physical material itself — it does not typically address authorship, and providers sometimes assume it implicitly does. State the expected credit (Resources role, acknowledgment, or a genuine collaboration with authorship on the table) explicitly, separate from the MTA’s legal terms. See CASRAI’s guide to the MTA process for how that document itself works, and the comparison of an MTA versus a Research Collaboration Agreement if the arrangement is closer to a genuine collaboration than a one-way transfer.
- Ask what role the provider expects, not just whether they expect “credit.” “Credit” is ambiguous between authorship and acknowledgment; naming the specific CRediT role (Resources, or Resources plus others) removes the ambiguity before drafting begins.
- Revisit the question if the collaboration grows. A relationship that starts as a one-off reagent request sometimes evolves into ongoing consultation on the project. If it does, reassess against all four ICMJE criteria at the point of manuscript preparation, not against the terms of the original request.
- Get written agreement to be acknowledged. Because an acknowledgment can imply the acknowledged person endorses the paper’s data and conclusions, ICMJE recommends that corresponding authors get the acknowledged individual’s written permission before naming them — a useful habit for material providers as much as for any other acknowledged contributor.
For disputes that do arise after the fact — a material provider who feels shortchanged after the paper is drafted or submitted — the Committee on Publication Ethics (COPE) provides guidance and flowcharts for resolving authorship disagreements; see CASRAI’s overview of ICMJE versus COPE for how the two bodies’ roles differ.
Frequently asked questions
Does this apply the same way to human study participants, not just reagents and animal models?
Yes, in principle it’s the same analysis: providing access to a patient cohort or study population, on its own, is analogous to providing a cell line or reagent — it enables the research but is not itself conception/design, analysis/interpretation, or drafting. Clinical settings add their own layer of complexity around clinical-investigator group authorship and site-level acknowledgment conventions, which is a distinct topic from the lab-materials question this guide focuses on.
What if the material is genuinely novel and central to the paper’s contribution — doesn’t that change things?
Novelty and centrality affect how much the contribution matters to the field, not whether it independently satisfies the four ICMJE criteria. A uniquely valuable resource still needs to be paired with a design, analysis, or drafting contribution from that same person to justify authorship; absent that, the correct response to “this material was essential” is a prominent Resources credit or acknowledgment, not a byline.
Can a facility or core lab (rather than an individual) be listed instead of a named person?
Journals generally attribute authorship to individuals, not organizational units, and CRediT roles work the same way — a core facility is typically credited by naming the individual(s) responsible for the specific material or service, or acknowledged as a facility in the acknowledgments text, rather than treated as an author entity in its own right.
Does providing funding for the materials (rather than the materials themselves) change the analysis?
No. ICMJE separately lists “acquisition of funding” among the contributions that, alone, do not qualify a contributor for authorship — the same logic applies whether someone supplied the physical material or paid for it. The correct CRediT role for that contribution is Funding acquisition, and it’s commonly disclosed in a funding statement rather than an authorship byline.
